Cell Theranostics ‘s 3 chelator platforms are ideal for developing theranostic agents to diagnose and treat cancer and other diseases.
Theranostic medicine is a major step forward in making personalized medicine a reality. At Cell Theranostics, our vision is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level. Each Cell Theranostics diagnostic imaging compound and its companion therapeutic compound share the same target specific core. The clinical objective is to diagnose and stage the disease, determine the proper therapeutic dose level for the individual patient, treat the patient and follow-up by imaging the patient’s response to the therapy while the patient is undergoing the therapy.
The Astonish software, based on an advanced reconstruction algorithm, was originally developed for use with SPECT cameras through a collaboration with Philips Healthcare. The initial purpose of the software was to improve special resolution and reduce noise. In layman’s terms, Astonish software eliminates or substantially minimizes the blurring effect introduced by the collimator which is part of a SPECT camera. Today, practically all SPECT and SPECT/CT cameras utilize the Astonish reconstruction algorithm which, along with improvements in detector technology, has improved SPECT and SPECT/CT image quality on a par comparable to PET and PET/CT imaging. 99mTc-Oncardia will be in a position to take advantage of these improvements in image acquisition and display.